{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:05:06Z","timestamp":1791198306314,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2632,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13311-016-0430-x","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T09:36:17Z","timestamp":1459416977000},"page":"509-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV)"],"prefix":"10.1016","volume":"13","author":[{"given":"Peter G.E.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0430-x_bib1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM200003023420906","article-title":"Neurologic complications of the reactivation of varicella-zoster virus","volume":"342","author":"Gilden","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0430-x_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13550280390194000","article-title":"Herpes simplex virus-1 and varicella-zoster virus latency in human ganglia","volume":"9","author":"Mitchell","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-016-0430-x_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF03210846","article-title":"Varicella-zoster virus human ganglionic latency\u2014a current summary","volume":"16","author":"Kennedy","year":"2010","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-016-0430-x_bib4","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1073\/pnas.95.8.4658","article-title":"Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia","volume":"95","author":"Kennedy","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-016-0430-x_bib5","doi-asserted-by":"crossref","first-page":"10203","DOI":"10.1128\/JVI.01331-12","article-title":"Restricted varicella-zoster virus transcription in human trigeminal ganglia obtained soon after death","volume":"86","author":"Ouwendijk","year":"2012","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0430-x_bib6","doi-asserted-by":"crossref","first-page":"11893","DOI":"10.1128\/JVI.74.24.11893-11898.2000","article-title":"Varicella-zoster virus gene expression in latently infected human trigeminal ganglia","volume":"74","author":"Kennedy","year":"2000","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0430-x_bib7","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1099\/vir.0.000128","article-title":"A comparison of HSV-1 and VZV latency and reactivation","volume":"96","author":"Kennedy","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1007\/s13311-016-0430-x_bib8","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.1128\/JVI.74.24.11464-11471.2000","article-title":"Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR","volume":"74","author":"Cohrs","year":"2000","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0430-x_bib9","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/JVI.01862-10","article-title":"Varicella-zoster virus transcriptome in latently infected human ganglia","volume":"85","author":"Nagel","year":"2011","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0430-x_bib10","doi-asserted-by":"crossref","unstructured":"Steiner I, Budka,H, Chaudhuri A, et al. Viral encephalitis: guidelines for diagnosis and management. Eur J Neurol 2005; 12:331-343.","DOI":"10.1111\/j.1468-1331.2005.01126.x"},{"key":"10.1007\/s13311-016-0430-x_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/bmj.39206.571042.AE","article-title":"Herpes zoster","volume":"334","author":"Wareham","year":"2007","journal-title":"BMJ"},{"key":"10.1007\/s13311-016-0430-x_bib12","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Primers"},{"key":"10.1007\/s13311-016-0430-x_bib13","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.45.10.2771-2774.2001","article-title":"Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics","volume":"45","author":"Acosta","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s13311-016-0430-x_bib14","first-page":"303","article-title":"Recommendations for the management of herpes zoster","volume":"47","author":"Dworkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s13311-016-0430-x_bib15","doi-asserted-by":"crossref","unstructured":"Kennedy PGE, Montague P, Scott F, et al .Varicella-zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line. PLoS ONE 2013; 8 :e51570.","DOI":"10.1371\/journal.pone.0051570"},{"key":"10.1007\/s13311-016-0430-x_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1212\/01.WNL.0000148484.19070.4D","article-title":"Mahalingam R.VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy","volume":"64","author":"Gilden","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpainsymman.2004.01.014","article-title":"Treatment of postherpetic neuralgia: a review of therapeutic options","volume":"28","author":"Argoff","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1007\/s13311-016-0430-x_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1212\/01.WNL.0000140708.62856.72","article-title":"Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"63","author":"Dubinsky","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib19","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0430-x_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/archneur.63.7.noc60049","article-title":"Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir","volume":"63","author":"Quan","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-016-0430-x_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/13550289509111018","article-title":"Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia","volume":"1","author":"Mahalingam","year":"1995","journal-title":"J Neurovirol"},{"key":"10.1007\/s13311-016-0430-x_bib22","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0430-x_bib23","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0430-x_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11908-014-0407-z","article-title":"Update on varicella zoster virus vasculopathy","volume":"16","author":"Nagel","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1007\/s13311-016-0430-x_bib25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/01.wnl.0000258549.13334.16","article-title":"The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy","volume":"68","author":"Nagel","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.47.6.1441","article-title":"Varicella zoster virus, a cause of waxing and waning vasculitis: the New England Journal of Medicine case 5-1995 revisited","volume":"47","author":"Gilden","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib27","doi-asserted-by":"crossref","unstructured":"Kennedy PGE. Neurological complications of varicella-zoster virus infections. In Kennedy PGE, Johnson RT (eds) Infections of the Nervous System. Butterworths, 1987; 177-208.","DOI":"10.1016\/B978-0-407-02293-5.50015-5"},{"key":"10.1007\/s13311-016-0430-x_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.410350505","article-title":"Zoster sine herpete, a clinical variant","volume":"35","author":"Gilden","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0430-x_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1212\/WNL.0b013e31820a0d5d","article-title":"Zoster sine herpete: it would be rash to ignore it","volume":"76","author":"Kennedy","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/head.12425","article-title":"Giant cell arteritis","volume":"54","author":"Smith","year":"2014","journal-title":"Headache"},{"key":"10.1007\/s13311-016-0430-x_bib31","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.0000000000001459","article-title":"Varicella-zoster virus claims yet another painful scalp: giant cell arteritis","volume":"84","author":"Kennedy","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib32","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1212\/WNL.0000000000001409","article-title":"Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis","volume":"84","author":"Gilden","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0430-x_bib33","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/jamaneurol.2015.2101","article-title":"Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis","volume":"72","author":"Nagel","year":"2015","journal-title":"JAMA Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0430-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0430-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:44:20Z","timestamp":1761806660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1878747923009194"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0430-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Issues in the Treatment of Neurological Conditions Caused by Reactivation of Varicella Zoster Virus (VZV)","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0430-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}